Study S002174

Liraglutide Efficacy and Action on Type 2 Diabetes With Peripheral Atherosclerotic intErmittent Claudication (LEADPACE STUDY): a Prospective, 24-week, Multicenter, Randomized, Controlled Clinical Study

ClinicalTrials.gov record

Registration

Registration: NCT04146155
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: UNKNOWN
Enrollment: 200
Start: 2020-05-01
Primary completion: 2021-12-31
Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions: Type 2 Diabetes; Peripheral Vascular Disorder Due to Diabetes Mellitus
Interventions: DRUG:Liraglutide+standard-of-care treatment; OTHER:standard-of-care treatment
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Initial and absolute claudication distance [24 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0029105	Novel antidiabetic therapies in patients with peripheral artery disease: current perspective. Janić M, Frontiers in clinical diabetes and healthcare	2024	Randomized trial	PMID 39659952 DOI	cites ClinicalTrials.gov:NCT04146155
R0016220	Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope? Caruso P, Diabetes/metabolism research and reviews	2023	Randomized trial	PMID 36812501 DOI	cites ClinicalTrials.gov:NCT04146155
R0011646	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Kanie T, The Cochrane database of systematic reviews	2021	Systematic review	PMID 34693515 DOI	cites ClinicalTrials.gov:NCT04146155; registry reference DERIVED:34693515